Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 20.0 kDa. The protein migrates as 28-38 kDa under reducing (R) condition, and 26-36 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human CD7 Protein, His,Avitag, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Human CD7 Protein, His,Avitag, premium grade (Cat. No. CD7-H82E4) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.
2e5 of Anti-CD7 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human CD7 Protein, His,Avitag, premium grade (Cat. No. CD7-H82E4) and negative control protein respectively, washed and then followed by PE-Streptavidin and analyzed with FACS (QC tested).
Immobilized Anti-CD7 antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human CD7 Protein, His,Avitag, premium grade (Cat. No. CD7-H82E4) with a linear range of 0.5-8 ng/mL (QC tested).
Immobilized Biotinylated Human CD7 Protein, His,Avitag, premium grade (Cat. No. CD7-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).
Price(USD) : $380.00
Price(USD) : $1645.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
BEAM-201 | BEAM-201 | Phase 2 Clinical | Beam Therapeutics Inc | Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, T-Cell | Details |
CD7-specific CAR-T Cell therapy(Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
CD7 CAR-T cell therapy(The General Hospital Of Western Theater Command) | Phase 2 Clinical | The General Hospital Of Western Theater Command | Leukemia | Details | |
CTD-402 | CTD-402; CTD402 (CD7) | Phase 2 Clinical | Nanjing Bioheng Biotech Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD5/CD7-Specific CAR-T Cells therapy(Essen Biotech) | BAH246; BAH-246; EB-BH2026 | Phase 2 Clinical | Essen Biotech | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell; Central Nervous System Diseases; Leukemia, T-Cell | Details |
Autologous and Donor-derived CD7 CAR-T Therapy(Beijing GoBroad Hospital) | Phase 2 Clinical | Beijing GoBroad Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD7-CAR-T Cells Therapy | CD7-CART01 | Phase 2 Clinical | Bambino Gesu Hospital And Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Humanized CD7 CAR-T cells | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma, T-Cell | Details | |
WU-CART-007 | WU-CART-007 | Phase 2 Clinical | Wugen Inc | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, Extranodal NK-T-Cell; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Mycosis Fungoides; Leukemia, T-Cell; Angioimmunoblastic T-cell Lymphoma | Details |
Anti-CD7 CAR T-cell therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Still's Disease, Adult-Onset; Hematologic Diseases; Leukemia; Osteochondrodysplasias; Dermatomyositis; Autoimmune Diseases; Neoplasms; Bone Marrow Failure Disorders; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Colitis, Ulcerative; Lymphoma; Lymphoma, T-Cell; Crohn Disease; Leukemia, T-Cell | Details | |
CD7.CAR/28zeta CAR T cells | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Angioimmunoblastic T-cell Lymphoma; Leukemia, Prolymphocytic; Mycosis Fungoides | Details | |
GC-027 | GC-027 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
MB-107(March Biosciences) | MB-107(March Biosciences) | Phase 1 Clinical | March Biosciences Inc | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell | Details |
INT-2104 | INT-2104 | Phase 1 Clinical | Interius BioTherapeutics Inc | Lymphoma, B-Cell; Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
RD-13 | RD13-02; RD 13 02; RD-13; RD-13-01; CTD-401 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Hematologic Neoplasms; Hematologic Diseases; Neoplasms; Anemia, Aplastic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell | Details |
Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics) | BT-007 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, Bioceltech Therapeutics Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
BE CAR-7 | BE-CAR-7 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Prolymphocytic, T-Cell | Details |
Anti-CD7 CAR-T cell Therapy (Shanghai Jiao Tong University Affiliated First People'S Hospital) | Phase 1 Clinical | Shanghai Jiao Tong University Affiliated First People'S Hospital | Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Angioimmunoblastic T-cell Lymphoma | Details | |
Anti-CD19/CD7 UCAR-T cell therapy (Gracell) | GC-502 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD7 CARvac T cell therapy | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
SenL-T7 CAR T Cells (Hebei Senlang Biological) | Senl-T7; Senl-T-7; SENL-101 | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Leukemia, T-Cell | Details |
PA3-17 | PA3-17; PA-3-17; PA3-17 (autologous) | Phase 1 Clinical | Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
CD7 CAR-T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
PCART7-CD3 | PCART7-CD3 | Clinical | National University Of Singapore | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This web search service is supported by Google Inc.